The Evaluation of Chenopodium Formosanum and Fagopyrum Esculentum Extract on Anti-aging Effect
NCT ID: NCT04237818
Last Updated: 2020-11-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2020-02-01
2020-08-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo drink
Placebo drink
consume 2 bottle (30 mL) per day for 56 days
Chenopodium Formosanum and Fagopyrum Esculentum Extract drink
Chenopodium Formosanum and Fagopyrum Esculentum Extract drink
consume 2 bottle (30 mL) per day for 56 days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo drink
consume 2 bottle (30 mL) per day for 56 days
Chenopodium Formosanum and Fagopyrum Esculentum Extract drink
consume 2 bottle (30 mL) per day for 56 days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects must read and sign the informed consent form after the study has been fully explained.
* Subjects are willing to cooperate and comply with all of the regulation during the trial.
* Subject should inform to investigator immediately if adverse effect is happened.
* Subjects are willing to avoid UV overexposure during the trial (include indoor tanning treatment).
Exclusion Criteria
* Subjects who have severe desquamation, tattoo, sunburn, peeling skin or other skin condition might impact measurement.
* Subjects with any physical condition judged by the researcher not to be eligible for this study.
* Subjects with uncontrollable physical condition such as high blood pressure, thyroid disease, diabetes, etc.
* Female who is pregnant or nursing or planning to become pregnant during the course of the study.
* Those who are currently participating in other clinical trials or who have just concluded a clinical trial two weeks ago.
* Women who have started contraceptive or change current hormone contraceptive methods within 3 months.
20 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
TCI Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hsiu-Mei Chiang, Prof.
Role: PRINCIPAL_INVESTIGATOR
China Medical University, China
Po-Yuan Wu, Dr.
Role: STUDY_DIRECTOR
China Medical University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
China Medical University
Taichung, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CMUH108-REC1-147
Identifier Type: -
Identifier Source: org_study_id